论文部分内容阅读
由于担心大肠杆菌污染的废水排出,环境科学家一直极力阻止在西德的黑森州建立重组体胰岛素的试验性工厂,该工厂是由 Hoechst 公司设计的。在黑森州环境部举行关于安全问题的公众听证会之后,该州一直拒绝允许开始建立这一工厂。Hoechst 公司坚持认为废水在排出之前将被消毒,但工厂的反对者们想方设法地提出许多问题。愈来愈多的问题已经使得 Hoechst 的 rDNA 胰岛素投放市场推迟了数月,并且黑森州近来的行动更将推迟产品的采用。然而,即使 Hoechst 被允许立即建立一个试验性的工厂,大
Environmental scientists have been trying to prevent the establishment of a pilot factory for recombinant insulin in Hessen, West Germany, which was designed by Hoechst, due to concerns about the discharge of wastewater contaminated by E. coli. After the Hessian Ministry of Environment held a public hearing on security issues, the state has refused to allow the establishment of the factory. Hoechst insists that the waste water will be disinfected before it is discharged, but the factory’s opponents are trying to put forward many questions. More and more problems have delayed the launch of Hoechst’s rDNA insulin for several months, and recent actions in Hessen will delay product adoption. However, even if Hoechst was allowed to immediately establish a pilot plant,